Tuesday, August 29, 2017 10:15 PM ET
Significant Insider purchase Extends the buy Trend of Last 90 Days in Shares of Regeneron Pharmaceuticals (REGN)
An insider — Sanofi, 10% Owner — acquired 72,378 shares of Regeneron Pharmaceuticals having a market value of approximately $34,840,133 today, as disclosed in a form 4 document filed with the SEC. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 302,465 company shares and the sale of 56,213 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 318,630 shares and have averaged 143,685 shares per transaction over this time period.
The number of insider buy/sell trades at Regeneron Pharmaceuticals is higher than the 265 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 322 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for Regeneron Pharmaceuticals insiders was also higher. Within the peer group there were 7,839,981 shares purchased and 14,536,406 shares sold with company insiders having sold 20,796 shares on average.
In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data obtained to evaluate and write this story.
Using proprietary artificial intelligence methods, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.